Portal:AOP/FeaturedPathways
From WikiPathways
(Difference between revisions)
Current revision (08:38, 7 January 2021) (view source) |
|||
| (One intermediate revision not shown.) | |||
| Line 3: | Line 3: | ||
|width=100px|{{#pwImage:Pathway:WP4945|250px||Mitochondrial Complex I inhibition leading to parkinsonian motor deficits (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP4945|250px||Mitochondrial Complex I inhibition leading to parkinsonian motor deficits (Homo sapiens)}} | ||
|width=100px|{{#pwImage:Pathway:WP4944|250px||Mitochondrial Complex I inhibition leading to chemical induced fanconi syndrome (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP4944|250px||Mitochondrial Complex I inhibition leading to chemical induced fanconi syndrome (Homo sapiens)}} | ||
| - | | | + | |width=100px|{{#pwImage:Pathway:WP5034|250px||Mitochondrial Complex inhibition leading to liver injury (Homo sapiens)}} |
|- | |- | ||
|width=100px|{{#pwImage:Pathway:WP3980|250px||Protein alkylation leading to liver fibrosis (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP3980|250px||Protein alkylation leading to liver fibrosis (Homo sapiens)}} | ||
| Line 23: | Line 23: | ||
|width=100px|{{#pwImage:Pathway:WP3890|250px||Nanomaterial induced inflammasome activation (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP3890|250px||Nanomaterial induced inflammasome activation (Homo sapiens)}} | ||
|width=100px|{{#pwImage:Pathway:WP3181|250px||Nanoparticle-mediated activation of receptor signaling (Bos taurus)}} | |width=100px|{{#pwImage:Pathway:WP3181|250px||Nanoparticle-mediated activation of receptor signaling (Bos taurus)}} | ||
| - | |} | + | |width=100px|{{#pwImage:Pathway:WP5035|250px||ACE2 inhibition leads to lung fibrosis (Homo sapiens)}} |
| + | |- | ||
| + | | | ||
List of featured pathways: | List of featured pathways: | ||
| Line 44: | Line 46: | ||
* [[Pathway:WP4944]] | * [[Pathway:WP4944]] | ||
* [[Pathway:WP4945]] | * [[Pathway:WP4945]] | ||
| + | * [[Pathway:WP5034]] | ||
| + | * [[Pathway:WP5035]] | ||
Current revision
|
Image does not exist COVID-19 AOP (Homo sapiens) |
Image does not exist Mitochondrial Complex I inhibition leading to parkinsonian motor deficits (Homo sapiens) |
Image does not exist Mitochondrial Complex I inhibition leading to chemical induced fanconi syndrome (Homo sapiens) |
Image does not exist Mitochondrial Complex inhibition leading to liver injury (Homo sapiens) |
|
Image does not exist Protein alkylation leading to liver fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Mus musculus) |
Image does not exist Epilepsy Adverse Outcome Pathway (Homo sapiens) |
|
Image does not exist Liver steatosis AOP (Homo sapiens) |
Image does not exist Steatosis AOP (Homo sapiens) |
Image does not exist Selective serotonin reuptake inhibitors lead to several adverse outcomes (Homo sapiens) |
Image does not exist Gastric ulcer formation (Homo sapiens) |
|
Image does not exist Nanoparticle-mediated activation of receptor signaling (Homo sapiens) |
Image does not exist Nanomaterial induced apoptosis (Homo sapiens) |
Image does not exist Nanoparticle triggered regulated necrosis (Homo sapiens) |
Image does not exist Nanoparticle triggered autophagic cell death (Homo sapiens) |
|
Image does not exist Overview of nanoparticle effects (Homo sapiens) |
Image does not exist Nanomaterial induced inflammasome activation (Homo sapiens) |
Image does not exist Nanoparticle-mediated activation of receptor signaling (Bos taurus) |
Image does not exist ACE2 inhibition leads to lung fibrosis (Homo sapiens) |
|
List of featured pathways: |
